Verastem VSTM
today announced the initiation of a Phase 1 trial of VS-5584, a dual
mTORC1/2 and PI3K inhibitor, in patients with advanced solid tumors or
lymphoma.
“Initiation of the clinical development of VS-5584 is an important
milestone for Verastem,” said Dr. Joanna Horobin, Verastem Chief Medical
Officer. “We are conducting this study with clinical investigators who
have extensive experience with PI3K and mTOR inhibitors and applying our
expertise in cancer stem cell biology to progress the development of the
compound.”
Verastem presented preclinical research at the American Association
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in